CR20240043A - Compuestos de heteroarilo para tratar la enfermedad de huntington - Google Patents

Compuestos de heteroarilo para tratar la enfermedad de huntington

Info

Publication number
CR20240043A
CR20240043A CR20240043A CR20240043A CR20240043A CR 20240043 A CR20240043 A CR 20240043A CR 20240043 A CR20240043 A CR 20240043A CR 20240043 A CR20240043 A CR 20240043A CR 20240043 A CR20240043 A CR 20240043A
Authority
CR
Costa Rica
Prior art keywords
disease
compounds
heteroaryl compounds
treating huntington
forms
Prior art date
Application number
CR20240043A
Other languages
English (en)
Inventor
Anuradha Bhattacharyya
Matthew S Eastwood
Hongyu Ren
Rauful Alam
Jana Narasimhan
Nanjing Zhang
Guangming Chen
Yao Jiang
Gary Mitchell Karp
Seyedmorteza Hosseyni
Nadiya Sydorenko
Suresh Babu
Matthew G Woll
Young-Choon Moon
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of CR20240043A publication Critical patent/CR20240043A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente descripción se refiere a compuestos, formas y composiciones farmacéuticas de los mismos y métodos de uso de dichos compuestos, formas o composiciones de los mismos para tratar o mejorar la enfermedad de Huntington. En particular, la presente descripción se refiere a compuestos de heteroarilo bicíclicos sustituidos, formas y composiciones farmacéuticas de los mismos y métodos de uso de dichos compuestos, formas o composiciones de los mismos para tratar o mejorar la enfermedad de Huntington.
CR20240043A 2021-07-30 2022-07-29 Compuestos de heteroarilo para tratar la enfermedad de huntington CR20240043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163203761P 2021-07-30 2021-07-30
PCT/US2022/038870 WO2023009816A1 (en) 2021-07-30 2022-07-29 Heteroaryl compounds for treating huntington's disease

Publications (1)

Publication Number Publication Date
CR20240043A true CR20240043A (es) 2024-05-22

Family

ID=83149486

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240043A CR20240043A (es) 2021-07-30 2022-07-29 Compuestos de heteroarilo para tratar la enfermedad de huntington

Country Status (16)

Country Link
US (1) US20240336613A1 (es)
EP (1) EP4377317A1 (es)
JP (1) JP2024528066A (es)
KR (1) KR20240054264A (es)
CN (1) CN118159539A (es)
AR (1) AR126612A1 (es)
AU (1) AU2022320725A1 (es)
CA (1) CA3227287A1 (es)
CL (1) CL2024000250A1 (es)
CO (1) CO2024000890A2 (es)
CR (1) CR20240043A (es)
IL (1) IL310440A (es)
MX (1) MX2024001417A (es)
PE (1) PE20240929A1 (es)
TW (1) TW202321247A (es)
WO (1) WO2023009816A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
HRP20240935T1 (hr) 2018-06-27 2024-11-22 Ptc Therapeutics, Inc. Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
JP7649257B2 (ja) 2019-05-13 2025-03-19 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
CA3249778A1 (en) * 2022-06-15 2023-12-21 Ptc Therapeutics, Inc. HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240935T1 (hr) 2018-06-27 2024-11-22 Ptc Therapeutics, Inc. Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
EP3814360B8 (en) * 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020190793A1 (en) * 2019-03-15 2020-09-24 Skyhawk Therapeutics, Inc. Compositions and methods for correction of aberrant splicing

Also Published As

Publication number Publication date
WO2023009816A1 (en) 2023-02-02
JP2024528066A (ja) 2024-07-26
TW202321247A (zh) 2023-06-01
AR126612A1 (es) 2023-10-25
PE20240929A1 (es) 2024-04-30
MX2024001417A (es) 2024-05-14
EP4377317A1 (en) 2024-06-05
CO2024000890A2 (es) 2024-04-29
CA3227287A1 (en) 2023-02-02
CN118159539A (zh) 2024-06-07
CL2024000250A1 (es) 2024-07-12
KR20240054264A (ko) 2024-04-25
IL310440A (en) 2024-03-01
US20240336613A1 (en) 2024-10-10
AU2022320725A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
CR20240043A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
MX2020009957A (es) Compuestos para el tratamiento de enfermedad de hungtinton.
ZA202100208B (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2018226622A8 (en) Compounds for treating huntington's disease
ZA202403923B (en) Heterocyclic compounds as immunomodulators
PH12018501226A1 (en) Methods for treating huntingtons disease
MX2024014435A (es) Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2022008456A (es) Inhibidores de mek y usos terapeuticos de estos.
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
MX2025015186A (es) Inhibidores de pi3k y uso de estos
MX2024013838A (es) Compuestos y usos de estos
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
BR0315801A (pt) Compostos piridopirimidinona, eu processo de preparação e as composições farmacêuticas que os contêm
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
ZA202400821B (en) Inhibitors of transglutaminases
SE9903894D0 (sv) Novel compounds
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
ZA202400823B (en) Inhibitors of transglutaminases